Syngene International and Deerfield have signed an agreement to collaborate to advance therapeutic discovery projects, from target validation through to pharmacological proof of concept and preclinical evaluation.
This five-year collaboration unites the core skills of the investment management company Deerfield, through its drug discovery and development arm 3DC, and Syngene's integrated drug discovery (IDD) services. Deerfield Discovery and Development Corporation (3DC) is the drug discovery and development subsidiary of Deerfield Management Company (Deerfield).
3DC has selected Syngene as a key execution partner for a developing portfolio of molecular entities, spanning multiple therapeutic areas and modalities. The ultimate goal is to deliver much needed benefit to patients suffering from serious, unmet medical needs through innovation, scale, quality, and speed-to-market. The collaboration will start with immediate effect and is expected to run for an initial cycle of 5 years.
The announcement was made after market hours yesterday, 19 November 2020. Shares of Syngene International fell 0.98% to settle at Rs 567.40 yesterday.
Syngene International is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)